Key Takeaways
- Revenue up 12%, EBITDA up 37%: Q2 revenue hit ₹375.8 crore with EBITDA margin expanding 506 bps to 28%, driven by MSA executions.
- Capacity expansion pulled forward a full year: Phase 2 will now be ready by end of CY26, with 22 crore units of installed DDC capacity, as the order book forces management to stop onboarding new customers.
- The revenue recognition gap is the story: Management explicitly warned that reported numbers may not reflect the true scale of work underway, because take-or-pay and pre-launch manufacturing revenue often cannot be recognized until commercial shipment.
- Balance sheet stretched deliberately: Net debt rose to ₹903.3 crore and working capital to ₹593.6 crore, both tied to accelerated capex and inventory buildup for customer launches; management expects normalization over the medium term.
- What to watch next quarter: Whether semaglutide approvals outside Canada unlock revenue recognition in Q4, the pace of capacity coming online by May/June, and any specific FY27 guidance promised around end-March.
The Revenue Recognition Overhang
- Numbers may understate reality: Management cautioned investors directly that "our numbers may not necessarily reflect the true nature of the work that we are doing and the business opportunities that we are sitting on," because revenue recognition depends on contract language and accounting standards, not just activity levels.
- Take-or-pay complexity: These arrangements take multiple forms (capacity allocation fees, capex participation, reservation commitments), and some cannot be recognized as revenue until actual commercial shipment occurs, even if the capacity is fully utilized.
- Non-Canadian launches in Q4: Customers confident of approvals in markets outside Canada will get products manufactured in Q4, but how much revenue gets recognized depends entirely on how much material ships out before quarter-end.
- Next two quarters shaped by semaglutide approvals: The period will carry a "space of ambiguity" as customer regulatory timelines dictate what can be booked; management flagged this explicitly as a disconnect between reported numbers and underlying business momentum.
Arun Kumar: "I just wanted to be on this call to caution our investors that everything is hunky-dory, but our numbers may not necessarily reflect the true nature of the work that we are doing and the business opportunities that we are sitting on."
DDC: The Capacity-Constrained Engine
- Sold out, turning customers away: The company has stopped onboarding new DDC customers due to lack of capacity, with over 20 customers now in the fold and 8-10 launching next year across multiple global markets.
- Phase 2 accelerated by a year: Capacity expansion pulled forward aggressively; 22 crore units of installed capacity will be in place by end of CY26, with some capacity added as early as May or June.
- Headline capacity is not real capacity: Management stressed that 22 crore units will never translate to actual production; adjusted deliverable capacity is a function of product mix, changeover times, and other factors, and is priced at different points depending on volumes.
- Canada launch from March: OneSource is in the first wave of filers for semaglutide GLP launch in Canada, with relationships to remain an active player; India launches are a "no-brainer" with some partners already getting approval.
- Revenue per day, not utilization percentage: Management declined to give a capacity utilization range, redirecting investors to focus on the FY28 guidance and targeted revenue per day of filling irrespective of headline capacity.
Arun Kumar: "The adjusted capacity is a function of various factors, but the adjusted capacity will then be priced at a different price point depending upon the volumes. So consequently, your focus should be on our overall '28 guidance, which gives you a clear pathway."
Biologics & Injectables: The Next Legs
- Biologics traction driven by Biosecure: Significant momentum in the last two quarters as the US Biosecure Act forces innovator and biotech companies to seek new CDMO partners, combined with FDA and European simplification of biosimilar approval pathways.
- 4,000 liters already spoken for: Installed mammalian capacity expected to be fully taken, with management planning instant expansion; with limited capex, mammalian capacity can double from 4 kL to 8 kL.
- Injectables scaling on two tracks: Organic expansion adding new capabilities alongside the recently announced acquisition, positioning the company among leading sterile fill-finish CDMOs.
- Cross-selling validation: 12 customers are now common across modalities, proving the OneSource genesis story of a multi-modality CDMO.
- 50+ RFPs in non-GLP-1 modalities: While management did not disclose signed program numbers, the RFP pipeline signals broadening demand beyond the DDC anchor.
The End-to-End Moat
- Patient-ready box from one site: OneSource does development, commercial fill-finish for cartridges, packaging, boxing, and serialization, so the box a patient opens at home comes entirely from a single site.
- No known competitor globally: Management stated that no other CDMO, in India or globally, offers this integrated device-combination proposition at comparable scale.
- NATCO partnership adds first-to-file edge: A first-to-file situation with partner NATCO covers most SKUs in several regulated markets under a profit-share arrangement, adding a material exclusivity layer.
- MENA partnership progressing: An own-portfolio product partnered with a leading MENA player is expected to receive approval within the timeframe.
Neeraj Sharma: "Not only we do development for them, we will do commercial manufacturing for fill finish for cartridge, pack it, put it in the box, serialize it. So the box which a patient opens at home is the box coming out of one source site."
Balance Sheet & Capital Allocation
- Net debt up sharply: Rose ₹432.6 crore versus March 2025 to ₹903.3 crore, driven by accelerated capex investments for Phase 2 capacity expansion.
- Working capital elevated by design: ₹593.6 crore tied up in planned inventory buildup of long-lead items for upcoming DDC launches; purchases are made on behalf of customers backed by advances or commitments with valid purchase orders.
- Interest cost improving: Effective interest rate down 140 bps year-on-year to single digits, enabled by multiple credit rating upgrades since listing in January 2025, now in the A family.
- Acquisitions consolidating next year: The Poland and Brookes acquisitions are performing well and expected to start consolidating from the next financial year, subject to regular approval processes.
- Working capital normalization expected: Management anticipates the buildup will unwind over the medium term as launches convert inventory to revenue.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Phase 2 capacity ready | 22 crore units installed DDC capacity | End of CY26 (pulled forward by ~1 year) |
| Some capacity online earlier | Partial capacity addition | May or June |
| Canada semaglutide launch | First wave of filers, active player | From March |
| India launches | Expect to be in market on day one | As partner approvals come through |
| FY27 specific guidance | More specific guidance for next year and beyond | End of March, when non-Canada markets open |
| FY28 revenue outlook | ₹40 crore base business, ₹50 crore subject to shareholder approvals | Reiterated |
| Biologics capacity expansion | Mammalian capacity from 4 kL to 8 kL with limited capex | No date (demand-driven) |
| Acquisition consolidation | Poland and Brookes to start consolidating | Next financial year, subject to approvals |
| Working capital normalization | Inventory buildup to unwind | Medium-term |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹375.8 cr, +12% YoY |
| H1 FY26 revenue | ₹703 cr, +12% YoY |
| EBITDA | ₹106.5 cr, +37% YoY |
| EBITDA margin | 28%, expanded 506 bps YoY |
| H1 FY26 EBITDA | ₹195 cr, 28% margin |
| Adjusted PAT | ₹44.9 cr, versus negative PAT in prior-year quarter |
| Adjusted EPS (fully diluted) | ₹3.9 per share |
| Pro forma combined H1 revenue (OneSource plus incoming businesses) | ~US$110 mn, at ~30% EBITDA margin |
| FY28 revenue outlook | ₹50 cr (base business ₹40 cr plus inorganic), subject to shareholder approvals |
| Net debt | ₹903.3 cr, up ₹432.6 cr vs March 2025 |
| Working capital | ₹593.6 cr, elevated due to planned inventory buildup for DDC launches |
| Effective interest rate | Down 140 bps YoY, now in single digits |
| Customer and regulatory inspections (H1 FY26) | 37 successful inspections |
| New RFPs added in quarter | 26 |
| Customers common across modalities | 12 |
| Biologics funnel | ~4x of FY25 level |
| Installed biologics capacity (mammalian) | 4,000 liters, expandable to 8,000 liters with limited capex |
| DDC pen capacity target | Over 20 cr units ready by end of CY26, nearly a year ahead of prior schedule |
| Markets with patent expiry in March | 70+ |